Get started
Author

Dhana Sekhar Reddy Bandi

Observed names: D.S.R. Bandi, Dhana S. Bandi, Dhana S.R. Bandi, Dhana Sekar Reddy Bandi, Dhana Sekhar Reddy. Bandi, Dhanasekhar Reddy Bandi
ORCID: 0000-0003-0405-5503
Observed ORCID: 0000-0003-0405-5503
OpenAlex ID: A5071414858
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
2024 · Jeremy B. Foote, Tyler E. Mattox, et al. · Cancer Research · 25
Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions
2023 · Dhana Sekhar Reddy Bandi, Sujith Sarvesh, et al. · Cytokine & Growth Factor Reviews · 24
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
2025 · Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, et al. · Molecular Cancer · 22
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine
2024 · Ganji Purnachandra Nagaraju, Madhu Sudhana Saddala, et al. · Cell Reports Medicine · 17
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
2023 · Jeremy B. Foote, Tyler E. Mattox, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 13
PDF
Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis
2025 · Ganji Purnachandra Nagaraju, Madhu Sudhana Saddala, et al. · Cancer Letters · 11
Targeting cytokines: Reshaping the pancreatic tumor microenvironment
2025 · Dhana Sekhar Reddy Bandi, Siva Chander Chabattula, et al. · Cytokine & Growth Factor Reviews · 6
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma
2026 · Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
Abstract 5915: ADT-1004: A promising pan-RAS inhibitor for targeting KRAS mutations in pancreatic ductal adenocarcinoma
2024 · Dhana Sekhar Reddy Bandi, Purnachandra Nagaraju Ganji, et al. · Cancer Research · 3
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma
2024 · Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment
2026 · Dhana Sekhar Reddy Bandi, Sujith Sarvesh, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Abstract LB124: Oncogenic KRAS inhibition leverages senescence machinery to confer anti-tumor immunity in pancreatic ductal adenocarcinoma
2025 · Sujith Sarvesh, Dhana Sekar Reddy Bandi, et al. · Cancer Research · 1
Abstract B005: ADT-030, a novel PDE10 inhibitor that blocks RAS and β-catenin signaling with robust and durable antitumor activity and potential to mitigate resistance and on-target toxicities of monospecific RAS inhibitors
2026 · Xi Chen, Dhana S.R. Bandi, et al. · Clinical Cancer Research
Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Molecular Cancer
Additional file 6 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 10 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 2 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 5 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 12 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 9 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 3 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 4 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 7 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 1 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Additional file 11 of Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy
2026 · Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al. · Figshare
Works count: 41
Citation count: 127
H-index: 6
I10-index: 6
Year
Topic
Type